JP2008527039A5 - - Google Patents

Download PDF

Info

Publication number
JP2008527039A5
JP2008527039A5 JP2007552193A JP2007552193A JP2008527039A5 JP 2008527039 A5 JP2008527039 A5 JP 2008527039A5 JP 2007552193 A JP2007552193 A JP 2007552193A JP 2007552193 A JP2007552193 A JP 2007552193A JP 2008527039 A5 JP2008527039 A5 JP 2008527039A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
aryl
heterocyclyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007552193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008527039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/001365 external-priority patent/WO2006078575A2/en
Publication of JP2008527039A publication Critical patent/JP2008527039A/ja
Publication of JP2008527039A5 publication Critical patent/JP2008527039A5/ja
Withdrawn legal-status Critical Current

Links

JP2007552193A 2005-01-19 2006-01-13 有糸分裂キネシン阻害剤としてのフッ素化アミノアルキル−4−オキソ−3,4−ジヒドロピリド[3,4−d]ピリジン Withdrawn JP2008527039A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64490705P 2005-01-19 2005-01-19
PCT/US2006/001365 WO2006078575A2 (en) 2005-01-19 2006-01-13 Fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido[3,4- d] pyrimidines as inhibitors of mitotic kinesins

Publications (2)

Publication Number Publication Date
JP2008527039A JP2008527039A (ja) 2008-07-24
JP2008527039A5 true JP2008527039A5 (cg-RX-API-DMAC7.html) 2009-02-26

Family

ID=36692759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007552193A Withdrawn JP2008527039A (ja) 2005-01-19 2006-01-13 有糸分裂キネシン阻害剤としてのフッ素化アミノアルキル−4−オキソ−3,4−ジヒドロピリド[3,4−d]ピリジン

Country Status (7)

Country Link
US (1) US7632839B2 (cg-RX-API-DMAC7.html)
EP (1) EP1855664A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008527039A (cg-RX-API-DMAC7.html)
CN (1) CN101193637A (cg-RX-API-DMAC7.html)
AU (1) AU2006206652A1 (cg-RX-API-DMAC7.html)
CA (1) CA2595130A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006078575A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346988B1 (en) * 2008-10-31 2017-05-31 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
UY32922A (es) * 2009-10-06 2011-04-29 Bayer Schering Pharma Ag Derivados de 3, 5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina fluoro-sustituidos y procedimientos de uso de los mismos
CN103298469A (zh) 2010-08-31 2013-09-11 首尔大学校产学协力财团 PPARδ激动剂的胎儿重编程的用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005530806A (ja) * 2002-05-23 2005-10-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害薬
WO2005046588A2 (en) * 2003-11-07 2005-05-26 Cytokinetics, Inc. Compounds, compositions, and methods

Similar Documents

Publication Publication Date Title
JP2008527038A5 (cg-RX-API-DMAC7.html)
Lang et al. Nitrogen-containing heterocycles as anticancer agents: An overview
JP5931982B2 (ja) (a)ホスホイノシタイド3−キナーゼ阻害剤および(b)Ras/Raf/Mek経路のモジュレーターの配合物
JP2022088616A (ja) 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法
JP2022520061A5 (cg-RX-API-DMAC7.html)
JP2018531983A (ja) タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
JP2009514881A5 (cg-RX-API-DMAC7.html)
US20090054415A1 (en) Combinations, methods and compositions for treating cancer
RU2017104909A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
JP2018504418A5 (cg-RX-API-DMAC7.html)
JP2007517071A5 (cg-RX-API-DMAC7.html)
JP2009541223A5 (cg-RX-API-DMAC7.html)
JP2009516653A5 (cg-RX-API-DMAC7.html)
JP2020523354A5 (cg-RX-API-DMAC7.html)
CN108779073A (zh) 用于治疗癌症的组合物和方法
KR20130048293A (ko) 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
RU2015108755A (ru) Комбинация ингибитора pik3 и ингибитора с-мет
RU2014150860A (ru) Режим дозирования pi-3 киназы
MX2007004549A (es) Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
JP2008527041A5 (cg-RX-API-DMAC7.html)
JP2013511526A5 (cg-RX-API-DMAC7.html)
TW202102216A (zh) 抗腫瘤組合物
JP2014512362A5 (cg-RX-API-DMAC7.html)
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
AU2016296997B2 (en) Chlorobenzene substituted azaaryl compounds